Mood No. 31

Mind Soak

MOOD NO. 31

Emotional Stability Complex

Formulated for sustained mood support

Low mood, emotional flatness, and persistent sadness are not character deficiencies. In most cases, they reflect identifiable neurochemical and nutritional insufficiencies — inadequate serotonin precursor availability, impaired methylation, deficient omega-3 status, or vitamin D deficiency — all of which are addressable through targeted nutritional support.

This formula does not force serotonin output. It provides the raw materials, cofactors, and structural conditions that allow your brain to produce and regulate its own serotonin, dopamine, and norepinephrine — the three monoamines most directly implicated in mood, motivation, and emotional resilience.

This is not antidepressant replacement. It is foundational neurochemical support — addressing the deficits that make mood dysregulation more likely and antidepressant response less robust.

Safe to take alongside most antidepressants and mood stabilizers with one important exception: 5-HTP requires prescriber review before combining with SSRIs, SNRIs, MAOIs, or any other serotonergic agent. See the highlighted note in the dosing section below.
⚠ Clinical Notice — Serotonin Syndrome Risk

This formula contains 5-HTP, a direct serotonin precursor. Combining 5-HTP with SSRIs (sertraline, escitalopram, fluoxetine, etc.), SNRIs (venlafaxine, duloxetine), MAOIs, tramadol, or triptans without prescriber guidance carries a risk of serotonin syndrome. Do not take this formula concurrently with serotonergic medications without first consulting your prescribing provider.

Formula Ingredients

Omega-3 EPA (AvailOm®)

600 mg
31% EPA · 15% DHA · Algal-Sourced · Enhanced Bioavailability Form

What it does

EPA is the omega-3 fatty acid most specifically associated with mood regulation. It reduces neuroinflammation — the elevation of pro-inflammatory cytokines that directly suppresses tryptophan conversion into serotonin by upregulating the competing IDO pathway. In practical terms: high neuroinflammation means less serotonin, even when precursors are adequate. EPA also supports serotonin receptor expression, dopamine transmission, and myelin integrity. Meta-analyses of randomized controlled trials have demonstrated EPA-dominant formulations are significantly more effective for depression than DHA-dominant or balanced formulations. The ratio in this formula reflects this evidence base.


Why this dose

AvailOm® is a re-esterified triglyceride form of omega-3 with significantly higher bioavailability than standard ethyl ester fish oils — approximately 70% greater absorption per milligram. 600mg of AvailOm® delivers an effective EPA exposure equivalent to substantially higher doses of conventional fish oil. Clinical trials for depression have used 1,000–2,000mg EPA/day as ethyl esters; the AvailOm® form achieves meaningful plasma EPA elevation at this lower dose while also eliminating mercury exposure and being vegetarian-compatible.

5-Hydroxytryptophan (5-HTP)

150 mg

What it does

5-HTP is the immediate precursor to serotonin in the central nervous system. Unlike tryptophan, which must compete for transport across the blood-brain barrier, 5-HTP crosses freely and is converted directly to serotonin via aromatic L-amino acid decarboxylase — an enzyme whose activity is supported by the B6 present in this formula. Serotonin produced from 5-HTP is also the precursor to melatonin, supporting circadian rhythm and sleep quality. Clinical trials have demonstrated antidepressant, anxiolytic, and appetite-regulating effects. It begins producing measurable serotonergic effects within the first 1–2 weeks.


Why this dose

The clinical evidence base for 5-HTP spans 50–300mg/day. 150mg represents a balanced therapeutic dose — above the threshold for measurable antidepressant effect, but below the range where GI side effects become common at higher doses. It is appropriate as a daily baseline for mood support without the tolerability concerns associated with 200–300mg protocols. Important: Do not combine with SSRIs, SNRIs, MAOIs, or tramadol without prescriber guidance due to serotonin syndrome risk.

L-Theanine

250 mg

What it does

Anxiety and low mood are physiologically intertwined — elevated cortisol suppresses serotonin synthesis, and chronic sympathetic nervous system activation depletes monoamine reserves. L-theanine addresses this intersection directly. It increases alpha brain wave activity, elevates GABA, serotonin, and dopamine, and reduces glutamate-driven excitability. In the context of this formula, its role is to reduce the anxious overlay that frequently accompanies depressed mood — the hypervigilance, rumination, and stress reactivity that prevents the serotonergic support from stabilizing.


Why this dose

200mg is the validated threshold for anxiolytic and cognitive effects. This formula uses 250mg — slightly above the standard anxiolytic dose — to ensure meaningful GABAergic and serotonergic activity in individuals with a significant anxiety-mood comorbidity profile, which is the most common clinical presentation in mood disorders. This dose does not cause sedation during waking hours and does not impair cognitive performance.

Vitamin D

125 mcg (5,000 IU)
As Cholecalciferol (D3)

What it does

Vitamin D receptors are densely expressed in the hypothalamus, hippocampus, and prefrontal cortex. Vitamin D directly upregulates tryptophan hydroxylase, the rate-limiting enzyme in serotonin synthesis. Deficiency therefore functionally limits serotonin production regardless of precursor availability. Epidemiological data consistently links low serum 25-hydroxyvitamin D with elevated depression prevalence, and seasonal affective disorder is biologically linked to vitamin D insufficiency. Repletion studies in deficient populations show clinically meaningful improvements in depressive symptom scores.


Why this dose

5,000 IU (125mcg) of D3 is a therapeutic repletion dose appropriate for individuals with insufficient or deficient baseline vitamin D levels — a category that includes the majority of indoor-working adults in the northern hemisphere, individuals with darker skin pigmentation, and those who regularly use sunscreen. The standard 600–1,000 IU RDA is insufficient for repletion in most adults with documented deficiency. D3 (cholecalciferol) is used over D2 due to superior conversion to the active 25-OH form.

Folate (L-5-MTHF)

1,020 mcg DFE
As L-5-Methyltetrahydrofolate · Bypasses MTHFR Variants

What it does

L-methylfolate is the only form of folate that crosses the blood-brain barrier and participates directly in the methylation reactions required for monoamine neurotransmitter synthesis — specifically generating SAMe, the brain's primary methyl donor for serotonin, dopamine, and norepinephrine. MTHFR gene variants — present in 40–60% of the population — impair conversion of dietary folic acid to the active form. L-methylfolate is FDA-cleared as a medical food adjunct to antidepressants because of its demonstrated ability to improve antidepressant response rates in folate-insufficient individuals.


Why this dose

1,020mcg DFE of L-5-MTHF is a clinically meaningful dose that exceeds the standard 400mcg used for general folate sufficiency. It reflects the higher threshold needed to produce antidepressant-relevant effects on the methylation pathway. Critically, this bypasses the MTHFR conversion step entirely, making it effective regardless of genetic variants that impair folic acid processing. It works in direct biochemical partnership with B12; both are required at therapeutic doses for full methylation cycle effect.

Copper

1.5 mg
As Copper Bisglycinate Chelate

What it does

Copper is an essential cofactor for dopamine-beta-hydroxylase (DBH), the enzyme that converts dopamine into norepinephrine — the neurotransmitter responsible for drive, motivation, and stress resilience. Low copper status measurably impairs this conversion, resulting in relative norepinephrine deficiency. Copper also serves as a cofactor for monoamine oxidase and for ceruloplasmin, involved in antioxidant defense in neural tissue. Inadequate copper intake is common in populations supplementing with zinc, as zinc competes with copper for absorption.


Why this dose

1.5mg of copper bisglycinate chelate serves a dual purpose: it provides a clinically relevant dose for repletion of marginal copper deficiency, and it balances the zinc content (15mg) to maintain an appropriate zinc:copper ratio. The 10:1 zinc:copper ratio in this formula is consistent with standard clinical practice for preventing zinc-induced copper depletion. The bisglycinate chelate form is chosen for superior bioavailability over copper oxide.

Zinc

15 mg
As Zinc Picolinate

What it does

Zinc is the second most abundant trace metal in the brain, with particularly high concentrations in the hippocampus. It modulates NMDA glutamate receptor activity, supports BDNF expression, and regulates serotonin transporter activity. Multiple meta-analyses have established that serum zinc is consistently lower in individuals with depression relative to healthy controls, and zinc supplementation has demonstrated statistically significant reductions in depressive symptom scores both as monotherapy and as augmentation to antidepressants.


Why this dose

Zinc picolinate is among the most bioavailable forms, with picolinic acid acting as a natural chelator that facilitates intestinal absorption. 15mg is a therapeutic supplementation dose above the RDA (8–11mg/day) and within the well-tolerated range for daily supplementation (well below the UL of 40mg/day). Positive outcomes in depression augmentation studies have used 7–25mg/day. The paired 1.5mg copper in this formula is specifically included to maintain zinc:copper balance.

Magnesium Glycinate

100 mg

What it does

Magnesium serves a supporting role in this formula, contributing to NMDA receptor gating, HPA axis cortisol regulation, and GABA-A receptor function — mechanisms relevant to the anxiety component of mood disorders and to the neurochemical environment in which serotonin operates. Elevated cortisol from a dysregulated stress response directly suppresses serotonin synthesis; magnesium attenuates this suppression at the adrenal level. The glycinate-bound glycine also contributes independent inhibitory neurotransmitter activity.


Why this dose

100mg is a targeted supporting dose, not a full therapeutic anxiolytic dose. It is included to provide HPA axis and NMDA support in the context of a formula primarily designed around serotonergic and methylation pathways. Individuals who require more robust magnesium support — particularly those with significant anxiety burden alongside mood symptoms — may benefit from combining this formula with the Calm No. 41 formula, which provides an additional 400mg magnesium glycinate.

Vitamin B12

1,000 mcg
As Methylcobalamin · Active Methylated Form

What it does

Methylcobalamin is the second essential cofactor in the methylation cycle alongside L-methylfolate. Together, they drive the homocysteine-to-methionine conversion that produces SAMe — the universal methyl donor required for monoamine synthesis, DNA methylation, and myelin maintenance. B12 deficiency produces psychiatric symptoms clinically indistinguishable from primary mood disorders: fatigue, anhedonia, cognitive slowing, depressed mood, and emotional lability. Methylcobalamin is the neurologically active form and does not require hepatic conversion, unlike cyanocobalamin.


Why this dose

1,000mcg of methylcobalamin is a standard therapeutic oral dose used to address deficiency states and support the methylation pathway at full capacity. Because oral B12 absorption is limited by intrinsic factor availability (typically absorbing only 1–2% of high oral doses via passive diffusion), 1,000mcg ensures sufficient passive absorption even in individuals with impaired active transport. It works in direct biochemical partnership with the L-methylfolate in this formula; neither nutrient can complete the methylation cycle without the other.

How These Ingredients Work Together

Nine Ingredients. Four Converging Pathways.

🔗

Serotonin Production Chain

5-HTP pr